Ignite Creation Date:
2025-12-24 @ 11:13 PM
Ignite Modification Date:
2026-02-24 @ 8:50 AM
Study NCT ID:
NCT03308669
Status:
COMPLETED
Last Update Posted:
2019-11-27
First Post:
2017-10-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
Safety, Tolerability, and Pharmacokinetics of Lasmiditan When Co-administered With Topiramate in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2018-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the safety, tolerability and blood concentrations of lasmiditan and topiramate together compared to lasmiditan and topiramate separately. Information about any side effects that may occur will be collected.
Participants will be admitted to the Clinical Research Unit (CRU) one day prior to the start of the study and will remain through Day 14.
This study is expected to last approximately 25 days, not including screening. Screening is required within 28 days prior to the start of the study.
Participants will be admitted to the Clinical Research Unit (CRU) one day prior to the start of the study and will remain through Day 14.
This study is expected to last approximately 25 days, not including screening. Screening is required within 28 days prior to the start of the study.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| H8H-MC-LAHT | OTHER | Eli Lilly and Company | View |